title: CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab.
abstract: As a distinct type of aggressive mature large B-cell lymphoma, plasmablastic lymphoma (PBL) poses diagnostic and treatment challenges. PBL is distinguished from other B-cell lymphomas by the presence of plasmacytic differentiation markers such as CD38, CD138, and MUM1. Clinically, PBLs from oral and extra-oral sites are rapidly progressive tumors with frequent relapse after treatment with standard diffuse large B-cell lymphoma regimens. Here, we report a near-complete response of one patient with relapsed PBL following treatment with a non-cytotoxic regimen containing bortezomib, rituximab, and dexamethasone.
authors: Moores Cancer Center, University of California San Diego Health System, La Jolla, CA, USA.
authors: Min
authors: M
authors: Yan
authors: Zhaoming
authors: Z
authors: Dong
authors: Frank
authors: F
authors: Zhao
authors: Thomas
authors: T
authors: Chauncey
authors: Delva
authors: D
authors: Deauna-Limayo
authors: Jessica
authors: J
authors: Wang-Rodriguez
authors: Dayu
authors: D
authors: Liu
authors: Huan-You
authors: HY
authors: Wang
authors: Renate
authors: R
authors: Pilz
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D018951:Antigens, CD20 / Q000276:immunology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000008:administration & dosage*; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D001897:Boronic Acids; D011719:Pyrazines; D000069283:Rituximab; D000069286:Bortezomib
keywords: CD138; CD20; bortezomib; lymphoma; plasmablastic lymphoma; rituximab